Tag: Janus kinase

Since the first one was approved in 2012, Janus kinase (JAK) inhibitors—colloquially called the 'Jack family of drugs'—have become an important class of medication for treating various inflammatory and autoimmune conditions. These small-molecule drugs work by blocking specific signaling pathways inside immune cells that drive inflammation and disease.

Since the first approval in 2011, Janus Kinase (JAK) inhibitors have emerged as a powerful and fast-acting class of medications for inflammatory and autoimmune conditions. If you have seen the term "kak inhibitor" used, it is a common misspelling of these targeted immunomodulatory drugs. They work by interrupting specific signaling pathways within immune cells to reduce the overactive immune response that causes inflammation.

Discovered in the early 1990s, Janus kinases, or JAKs, are a family of intracellular non-receptor tyrosine kinases that play a critical role in cellular signaling. Understanding **what is a janus kinase?** is key to comprehending the fundamental JAK-STAT signaling pathway, which controls a vast range of cellular activities, from immune responses to cell growth.